Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment.
Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment.
复制标题
DOI：
10.1155/2012/686108
复制
发表时间：
2012
影响因子：
--
通讯作者：
Prakash S
中科院分区：
文献类型：
--
作者：
Abbasi S;Paul A;Shao W;Prakash S
大多数抗癌药物都受到它们引起的严重副作用的极大限制。多柔比星（DOX）是一种抗肿瘤药物，通常用于治疗乳腺癌。然而，它可能导致不可逆的心脏毒性，甚至可能导致充血性心力衰竭。为了避免这些对患者有害的副作用，并提高阿霉素的治疗效果，我们开发了载阿霉素的聚乙烯亚胺-（PEI-）增强的人血清白蛋白（HSA）纳米粒。所形成的纳米颗粒的尺寸为~137 nm，表面ζ电位为~+15 mV，使用每mg HSA添加20 μg PEI制备。用低分子量（25 kDa）PEI形成的空PEI增强的HSA纳米颗粒未观察到细胞毒性，表明纳米颗粒制剂的生物相容性和安全性。在优化的转染条件下，约80%的细胞转染与HSA纳米粒子含有四甲基罗丹明共轭牛血清白蛋白。总之，PEI增强的HSA纳米颗粒显示出发展成为抗癌药物的有效载体的潜力。
Most anticancer drugs are greatly limited by the serious side effects that they cause. Doxorubicin (DOX) is an antineoplastic agent, commonly used against breast cancer. However, it may lead to irreversible cardiotoxicity, which could even result in congestive heart failure. In order to avoid these harmful side effects to the patients and to improve the therapeutic efficacy of doxorubicin, we developed DOX-loaded polyethylenimine- (PEI-) enhanced human serum albumin (HSA) nanoparticles. The formed nanoparticles were ~137 nm in size with a surface zeta potential of ~+15 mV, prepared using 20 μg of PEI added per mg of HSA. Cytotoxicity was not observed with empty PEI-enhanced HSA nanoparticles, formed with low-molecular weight (25 kDa) PEI, indicating biocompatibility and safety of the nanoparticle formulation. Under optimized transfection conditions, approximately 80% of cells were transfected with HSA nanoparticles containing tetramethylrhodamine-conjugated bovine serum albumin. Conclusively, PEI-enhanced HSA nanoparticles show potential for developing into an effective carrier for anticancer drugs.